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Abstract.
BACKGROUND & OBJECTIVE: Whole genome sequencing has identified recurrent non-coding mutations that may
be important in carcinogenesis. We investigate the frequency of 5 such non-coding mutation hotspots in urothelial bladder
cancers (UBCs) and assess their potential for UBC detection and prognostication.
METHODS: DNA extracted from 302 UBCs was subjected to targeted next generation sequencing of non-coding mutation
hotspots in GPR126, PLEKHS1, TBC1D12, LEPROTL1 and WDR74. The frequency of mutations, and associations with
stage, grade, age, gender, smoking status, clinical outcomes, mutation signatures and gene expression were analysed using
χ2 tests, logistic regression and Cox proportional hazards models.
RESULTS: Non-coding mutations were common across all stages and grades of UBC. The frequencies were: GPR126
53.0%, PLEKHS1 38.7%, TBC1D12 25.5%, LEPROTL1 23.8% and WDR74 17.2%. There was an average of 1.6 mutations
per UBC, and 74% of UBCs harboured at least one mutation. They frequently co-occur, and commonly accompany an
APOBEC mutational signature. The mutations are not strongly associated with clinical parameters and are, most likely, early
events in the development of UBC.
CONCLUSIONS: Mutations at these 5 non-coding hotspots are common in UBC. Due to their high frequency across stages
and grades of disease, they should be included in UBC diagnostic biomarker panels.
Keywords: Bladder cancer, non-coding, mutations, prognosis, detection, DNA
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BACKGROUND
UBC is a common and heterogeneous malignancy
[1, 2]. It is considered to develop along one of two
routes - a papillary/low-grade pathway characterised
by activation of oncogenes and a diploid genome, and
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a carcinoma in situ (CIS)/high-grade pathway with
aneuploidy and a high mutation burden [3]. Gene
expression profiling can be used to separate UBCs
into up to 6 subtypes [4]; even within these pathways
and subtypes, considerable molecular and clinical
heterogeneity exists.
UBC is most frequently visually diagnosed by
flexible cystoscopy and confirmed by pathologi-
cal examination of transurethral resection or biopsy
specimens. At presentation, 75–80% of cases are
non-muscle invasive bladder cancer (NMIBC: stages
Ta/T1/Tis) [5], currently classed as being at low-,
intermediate- or high-risk of recurrence and/or pro-
gression to muscle-invasive bladder cancer (MIBC:
stages T2+) based on stage, grade, size, multiplic-
ity, concurrent CIS and prior recurrence rate [6].
NMIBC patients are subject to long-term surveillance
by flexible cystoscopy, which is both uncomfortable
for patients and expensive for healthcare providers.
Detection of UBC-related genomic alterations in
urine could enable non-invasive testing for UBC. We,
and others, have been investigating targeted deep-
sequencing of somatic mutations to develop such
a test [7–10]. Ideally one would target the mini-
mum number of mutations to maximise read depth,
reduce sequencing costs, and avoid false positive
results. Coding mutations are common in many genes
such as FGFR3, PIK3CA, KDM6A, STAG2 and TP53
(present in 20–50% of UBCs) [2, 10]. However,
more frequently mutated than any of these genes
is the TERT promoter [11–14]. TERT encodes the
catalytic subunit of the telomerase complex which
is upregulated in the majority of cancers and is
essential for telomere maintenance and overcoming
senescence [15]. Mutations in the TERT promoter at
chr5:1,295,228 and chr5:1,295,250 (hg19), 124 and
146 bp upstream of the transcription start site, gen-
erate consensus binding motifs for ETS transcription
factors, increasing TERT expression and activity, and
are associated with worse prognosis in UBC patients
[16, 17].
Recurrent mutations in other non-coding regions
have recently been identified in analyses of whole
genome sequencing (WGS) data. Weinhold et al.
identified non-coding variants in PLEKHS1 and
WDR74 in addition to the TERT promoter [18]. WGS
analyses have also identified non-coding variants in
TBC1D12, LEPROTL1 and GPR126 [19, 20]. In a
WGS study of 65 UBCs, Wu et al. confirmed the pres-
ence of recurrent non-coding mutations in GPR126,
PLEKHS1, TBC1D12, WDR74 and LEPROTL1, and
went on to validate GPR126 mutations in a further
196 UBCs [21]. Non-coding mutations in GPR126
have also been investigated in a cohort of 103 UBCs
[22], and non-coding mutations inPLEKHS1 in a sep-
arate cohort of 81 UBCs [7]. These studies suggest
that these mutations may be suitable for inclusion
in a UBC detection test due to their frequency and
occurrence at discrete hotspots.
In this study we use targeted deep-sequencing to
analyse non-coding regions in GPR126, PLEKHS1,
TBC1D12, LEPROTL1 and WDR74 in tumours from
302 UBC patients. These regions were selected on
the basis of published reports, albeit in a limited num-
ber of UBCs in some cases, that they are frequently
mutated [18–22]. However, these hotspots/putative
hotspots have not been studied in combination in a
large cohort of UBC patients. We report the frequen-
cies of these mutations across stages and grades of
disease and associations with clinical outcomes. We
also analyse the distributions of the mutations rela-
tive to one another, relative to mutational signatures,
their effects on gene expression and isoform usage,
and their potential as biomarkers for UBC.
MATERIALS AND METHODS
Patients and sample processing
Fresh-frozen tumours and whole blood were
collected as part of the West Midlands Bladder Can-
cer Prognosis Programme (BCPP, ethics approval
06/MRE04/65). Patients were recruited consecu-
tively from 2005 to 2011 from ten hospitals in the
West Midlands (UK), and gave informed consent for
enrolment based upon initial cystoscopic findings
suggestive of primary UBC. All patients were
newly-diagnosed and treatment-naı¨ve at biospeci-
men collection, and were subsequently treated and
monitored according to contemporary European
Association of Urology (EAU) guidelines (including
re-resection where indicated). Inclusion and exclu-
sion criteria are detailed elsewhere [23]. Where
necessary, tumour grade and stage records were
amended according to results of early re-resection or
cystectomy. We used the 1973 grade classification
as it was in universal use in the UK at the time
of patient recruitment, is the basis for the EORTC
and EAU NMIBC risk tables, and has comparable
utility to the 2004/2016 classification [24]. For
quality assurance, 10% of diagnostic formalin-fixed
paraffin-embedded tumour samples were retrieved
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Table 1
Patient characteristics
No. Grade Gender Mean age Smoking
cases (G1/G2/G3) (M/F) (years) (never, ever, current,
unknown)
Overall 302 61/73/168 237/65 70.8 49/167/66/20
pTa 140 61/59/20 106/34 68.8 26/74/29/11
pT1 88 0/14/74 79/9 71.1 14/49/23/2
MIBC 73 0/0/73 51/22 74.3 9/44/13/7
302 UBC patients were studied: 229 NMIBC patients (including one patient with
solitary CIS) and 73 MIBC patients. According to EAU risk stratification there were
34 LR-NMIBC, 67 IR-NMIBC and 128 HR-NMIBC.
from local histopathology departments and under-
went expert pathological review. All included
tumours were purely or predominantly urothelial
carcinomas. Tissues were collected at transurethral
resection (TURBT), snap-frozen, and stored at
–80◦C. DNA was extracted from tissues (25 mg)
and blood (100l) using DNeasy Blood and Tissue
kits (Qiagen). RNA was extracted from tissues using
RNeasy kits (Qiagen). Patient information is shown
in Table 1.
Non-coding mutation sequencing
Amplicon libraries were prepared by multiplex-
PCR using the primers shown in Table S1 and
30 cycles of target–specific PCR using Phusion
high-fidelity polymerase. Sample specific barcodes
were then incorporated in a second 15-cycle PCR.
Libraries were pooled, cleaned, mixed with 50%
PhiX and sequenced on a NextSeq mid-output flow-
cell to a mean depth of 9000x. Reads were aligned
to hg19 using bowtie2 version 2.2.6 in local mode.
Readcounts for each base at each position were
extracted using bam-readcount, with a minimum
mapping quality of 20 and a minimum base qual-
ity of 30 (-q 20 -b 30). Variant detection was based
on non-reference reads≥2.5% of the total read depth
and a minimum of 10 non-reference reads [9]. Recur-
rent mutations were defined as base substitutions
occurring in ≥2 UBCs (≥1 paired blood sample was
sequenced for each recurrent mutation to exclude
polymorphisms).
Additional sequencing
Sequencing of hotspots in 23 genes had previ-
ously been performed for all 302 UBCs in this study
[10]. In addition, RNAseq data had been generated
for 63 of the UBCs and exome sequencing data
for 71 of the UBCs prior to the current investi-
gation (manuscripts in preparation). RNA libraries
were prepared using Truseq Stranded Total RNA
with Ribo-zero Gold (Illumina) and exome libraries
using Nextera Rapid Capture (Illumina). Exome data
was quality checked with GATK (Genome Analysis
Tool Kit; v.3.6) and aligned to GRCh37 using BWA
(v.0.7.15). Somatic SNVs were called from pileup of
reads using binomial test comparing the number of
mutant and reference reads at the SNV site in the
tumour and the germline samples to that in the back-
ground of all germline samples. For each somatic
SNV the adjacent base upstream and downstream
was extracted to obtain the tri-nucleotide context and
deconstructSigs (v.1.8.0) used to infer the contribu-
tion of each of the 30 COSMIC mutational signatures
[25]. RNA-seq data was aligned to GRCh37 and reads
counted with STAR aligner (v2.5.2b). Normalisation
of read counts and differential expression analysis
between wt and mutated samples (controlling for
grade, stage and sequencing platform) was performed
using DESeq2 (v.1.18.1) in Bioconductor. Gene set
enrichment analysis was done using GAGE (v.2.28.2)
in Bioconductor with Gene Ontology, KEGG and
MSigDB gene set databases. Isoform expression was
quantified using Salmon (version 0.12.0 using stan-
dard parameters) on Gencode version 29 isoform
definitions [26].
Statistical analysis
Mutation frequencies were compared across
patient groups using χ2 tests or logistic regres-
sion models, where appropriate. The effect of
mutated genes on disease-specific survival, overall
survival and, for NMIBC, recurrence-free interval
was examined using Kaplan-Meier curves and the
Cox proportional hazards model.
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Fig. 1. Recurrent non-coding mutations in UBC. The boxplot shows the mutant allele frequencies for all recurrent mutations detected in
each gene. The bar charts show the number, type and position of recurrent mutations detected in each gene. Green bar = base change to A,
blue = to C, brown = to G, red = to T. Palindromic sequences are highlighted red. The WDR74 plot covers 105 bp. Variants present in a single
UBC and polymorphisms were not included in analyses but are shown in Table S2.
RESULTS
Mutation hotspots
The mutations detected within each amplicon are
shown in Fig. 1. The median mutant allele frequencies
for GPR126, PLEKHS1, TBC1D12 and LEPROTL1
ranged from 20–27% whilst the median mutant allele
frequency was somewhat lower for WDR74 at 12%.
These frequencies suggest that the mutations are
present in the majority of cancer cells within each
tumour rather than only in minor subclones. GPR126
was the most frequently mutated amplicon with muta-
tions occurring in 53.0% of UBCs, comprised mainly
of a G/A substitution at chr6:142706206 (n= 118)
or C/T at chr6:142706209 (n= 69) located between
exons 6 and 7, as previously reported [22]. PLEKHS1
was mutated in 38.7% of UBCs, with the most com-
mon events being G/A at chr10:115511590 (n= 65)
and C/T at chr10:115511593 (n= 58) located between
exons 1 and 2. TBC1D12 was mutated in 25.5%
of UBCs, with C/T at chr10:96162368 and G/A at
chr10:96162370 immediately upstream of the start
codon with mutations occurring 43 and 41 times
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respectively. LEPROTL1 was mutated in 23.8% of
UBCs, with the most common events being G/A at
chr8:29952919 (n= 36) and C/T at chr8:29952921
(n= 33) upstream of the start codon. Mutations in
WDR74 were observed in 17.2% of patients and
occurred predominantly at chr11:62609254 (34 cases
of G/A and 12 cases of G/C) and at chr11:62609257
(6 cases of C/T and 2 cases of C/G), both upstream of
the start codon. Thus, the mutation hotspots in these 5
genes are all comprised of 2 discrete sites with 1 or 2
bases in-between and, with the exception of WDR74,
both sites exhibiting similar mutation rates. In 82%
of mutated amplicons, only one site is mutated (18%
doubly mutated). All of the mutation hotspots are
flanked by palindromic sequences that might form
loop structures (see Fig. 1).
Associations with stage, grade, age, gender and
smoking
Across the patient cohort, 223 UBCs had ≥1
mutated amplicon (73.8%) with an average of 1.6
mutated amplicons per UBC. All of the hotspots
are mutated across all stages and grades of disease
(Fig. S1 and Table S3), with ≥1 mutation present in
63.9%, 69.9% and 79.2% of grade 1, 2 and 3 UBCs,
respectively. All of the mutations were more com-
mon in older patients, although this only reached
statistical significance for TBC1D12 and GPR126
(p= <0.01 and 0.02 respectively). All of the mutations
were more common in males than females, although
this only reached statistical significance for GPR126
and LEPROTL1 (p= 0.018 and 0.033 respectively).
None of the mutations were strongly associated with
tobacco smoking, although GPR126, PLEKHS1 and
TBC1D12 mutation rates were significantly lower
in smokers than in ex-smokers or never smokers
(Table S3). GPR126 mutations were strongly associ-
ated with increasing stage and grade of disease (Fig.
S1), and were more frequent in larger and multifocal
tumours (Table S3).
Mutations and gene expression
Median levels of expression for the genes in wt
and mutant UBCs (n= 71), and in grade 1 and
grade 3 UBCs, are shown in Table S4. The expres-
sion of GPR126 is lower in GPR126 mutant UBCs
(p= 0.047), and substantially lower in grade 3 dis-
ease than grade 1 disease (p= 0.005). Although not
statistically significant, median PLEKHS1 expres-
sion was lower in PLEKHS1 mutant UBCs than in
wt UBCs but was significantly higher in grade 3
disease than grade 1 disease (p= 0.041) (Fig. S2).
Genome wide analysis did not identify many differen-
tially expressed genes between wt and mutant UBCs
but gene set enrichment analysis did detect some
altered pathways. The most significantly upregulated
pathways included “cell cycle” for LEPROT1 and
TBC1D12 mutants, mitochondrial genes were upreg-
ulated in GPR126 and WDR74 mutants and “cell
adhesion” was downregulated in PLEKHS1 mutants
(Supplemental Data). Our RNAseq dataset predomi-
nantly comprised NMIBC and we thus opted to use
the 117 genes used by Hedegaard et al. for NMIBC
subtyping [27], to cluster our UBCs (Fig. 2) rather
than a subtyping method based on MIBC (e.g. (2)).
The mutation frequency was 24% in group 1 (mostly
low grade pTa), 37% in group 3 (mostly high grade
NMIBC) and significantly higher (50%) in group 2
(high grade pT1 and MIBC) (p< 0.001). We also
utilised RNAseq data to investigate if non-coding
mutations in any of the genes influence gene isoform
expression; however, none of the mutations had an
influence (Fig. 3 and S3).
Non-coding mutations tend to co-occur and are
associated with an APOBEC signature
When tested in a pair-wise fashion, mutations in the
5 genes show highly significant co-occurrence (with
the exception of WDR74 & LEPROTL1 and WDR74
& TBC1D12). Mutational signatures were calculated
for 71 of the UBCs based on exome sequencing data
and separate logistic regression models were fitted
to determine the effect of the fraction of APOBEC
signature on the likelihood of having mutations in
the 5 genes (Supplemental Analysis Section 1.2.2).
Non-coding mutations in 4 of the genes (GPR126,
PLEKHS1,LEPROTL1 andTBC1D12) were strongly
associated with APOBEC signatures (p< 0.01, Fig. 4
and Supplemental Section 2.1.2)). Thus, it seems
likely that APOBEC activity is the common cause,
potentially explaining why these mutations are early
and widespread events in UBC.
Combining common non-coding and coding
mutations
A panel comprised of the non-coding mutation
hotspots in the 5 genes could detect 73.8% of
all UBCs. The patient characteristics of mutation
negative and positive cases were broadly similar
although the mutation negative cases were on aver-
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Fig. 2. The distribution of recurrent non-coding mutations across expression subtypes. Samples were clustered on the expression of 117
genes as described by Hedegaard et al. [27]. Expression levels are z-scores of regularized log counts, and the samples are clustered with
Pheatmap (v.1.0.10) using complete linkage hierarchical clustering and Euclidian distance.
age 3.7 years younger and slightly enriched for lower
stage and grade disease. In the same cohort of patients
TERT,FGFR3 or TP53 are mutated in 90.7% of cases
(data from [10]). Combining both sets of genes pro-
duces an 8-gene panel that is mutated in 95.4% of
UBCs (Fig. S4) and might prove useful for the non-
invasive detection of UBC via urinary DNA.
Associations with clinical outcomes
Overall survival times were compared for UBC
patients with or without mutations in each non-
coding region. Comparisons were made across the
entire cohort and for NMIBC and MIBC separately.
Survival curves for all comparisons are shown in
Supplemental data. None of the mutations were
significantly associated with worse overall survival
across the entire patient cohort. The most sig-
nificant association was for PLEKHS1 mutations
to predict better overall survival across the entire
patient cohort (p= 0.04) with the same trend in
both MIBC (p= 0.01) and NMIBC patients (p= 0.11)
(Fig. 5). WDR74 mutations are also associated
with better overall survival across the entire patient
cohort (p= 0.05) with the same trend in both MIBC
(p= 0.06) and NMIBC patients (p= 0.05).
DISCUSSION
We have studied non-coding mutations at 5 sites
across 302 UBCs of all stages and grades. The sites
are all close to or within protein coding genes: The
GPR126 and PLEKHS1 hotspots are intronic, the
TBC1D12 and LEPROTL1 hotspots are in 5’-UTRs
whereas the WDR74 hotspots are more than 1 kb
upstream of the transcription start site. Over 90% of
the mutations are C/T transitions and are flanked by
palindromic sequences that may form hairpin struc-
tures exposing these bases to APOBEC enzymes [20]
(as reported for S249C in FGFR3 [28]). Consis-
tent with this, non-coding mutations in 4 of these 5
genes are significantly more frequent in UBCs with a
higher APOBEC mutation signature. An association
between APOBEC signatures and the PLEKHS1 and
TBC1D12 hotspots was previously noted in breast
cancer [19].
The most frequently mutated gene, GPR126, is
a G-protein coupled receptor that can bind to base-
ment membrane protein type IV collagen [29]. The
effects of the non-coding mutations in GPR126 have
recently been investigated in 2 studies with appar-
ently discordant results [21, 22]. In a series of 196
patients, Wu et al. reported that GPR126 mutations
are more common in older patients and in NMIBC rel-
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Fig. 3. The effects of non-coding mutations on isoform usage. The graphs show the mean (+/– SEM) level of each transcript for each gene
as a fraction of all transcripts. Black bars = wt UBCs, grey bars = mutant UBCs.
Fig. 4. Co-occurrence of recurrent non-coding mutations and APOBEC signature. Each column in the table represents a UBC case; shaded
boxes indicate mutations. The histogram shows the fraction of the mutational burden attributable to ABOBEC activity (COSMIC signatures
2+13) from exome data for each UBC.
ative to MIBC, and immunohistochemistry showed
that UBCs with mutations expressed more GPR126
protein [21]. They also demonstrated significantly
worse overall survival for both NMIBC and MIBC
patients with mutations. In a series of 103 patients,
Garinet et al., reported GPR126 mutations at a sim-
ilar frequency in NMIBC and MIBC [22]; GPR126
mRNA levels were lower in mutant NMIBCs than
wt NMIBCs (with no difference between wt and
mutant in MIBC) and mutations were not signifi-
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Fig. 5. Effects of non-coding mutations in PLEKHS1 and WDR74 on overall survival in NMIBC and MIBC patients.
cantly associated with outcome. Our RNAseq data
are in agreement with Garinet et al’s finding that
GPR126 mutations decrease GPR126 mRNA lev-
els, and also that GPR126 mutations do not strongly
influence UBC outcomes.
PLEKHS1 encodes pleckstrin homology domain-
containing family S member 1, a paralog of GRB2
Associated Binding Protein 2; high expression lev-
els are associated with better outcome in the TCGA
UBC cohort (accessed via the human protein atlas
(proteinatlas.org)). Weinhold et al. showed decreased
PLEKHS1 gene expression in mutant tumours [18],
however we find no statistically significant link
betweenPLEKHS1mutations and expression in UBC
(Fig. S2). Recently, Pignot et al. reported no link
between PLEKHS1 mutations and expression and
that increased PLEKHS1 mRNA expression is a
poor prognostic indicator in UBC [30]. A role for
PLEKHS1mutations as diagnostic biomarkers is now
supported by multiple studies but biological and prog-
nostic roles require further investigation.
LEPROTL1 encodes Leptin Receptor Overlapping
Transcript Like 1. TBC1D12 encodes TBC1 Domain
Family Member 12 which is widely expressed in
human cancers and may act as a GTPase-activating
protein for Rab family proteins. Rheinbay et al.
demonstrated that both mutations in LEPROTL1,
but only chr10:96162368 and not chr10:96162370
mutations in TBC1D12, result in decreased gene
expression [20]; however, we did not observe these
effects in our data.
WDR74 encodes WD repeat-containing protein 74,
a relatively unstudied protein. Mutations in this non-
coding region are not restricted to just a double
mutation hotspot, but are more diverse and do not
appear to influence gene expression in either Wein-
hold’s pan-cancer analysis [18] or our RNAseq data.
Moreover, mutations at the two hotspots do not occur
at the same frequency, the palindromic sequences
are not as close to the mutations as for the other
hotspots, and no statistical link with APOBEC signa-
tures was found. Therefore, the WDR74 hotspot may
not be targeted by APOBEC, or be targeted with lower
efficiency. Nonetheless, our data suggest that the
non-coding WDR74 mutations confer an improved
prognosis in UBC.
R.R. Jeeta et al. / Non-Coding Mutations in Urothelial Bladder Cancer 271
None of the proteins encoded by these 5 genes are
known oncogenes or tumour suppressors. However,
they are all involved in pathways potentially associ-
ated with tumourigenesis and further investigation is
required to elicit their roles in UBC and to determine
whether these are driver mutations or passenger muta-
tions that simply reflect APOBEC activity. Despite
uncertainty regarding their biological role in UBC,
these frequent mutations are likely to be useful
biomarkers for the non-invasive detection of UBC via
urinary DNA sequencing although their occurrence
in non-neoplastic urothelium and benign neoplasms
remains to be defined. UBC associated mutations are
readily detectable in urinary DNA [7–10] and detec-
tion of PLEKHS1 mutations in the urine of UBC
patients has been demonstrated [7]; there is no rea-
son why the other mutations studied herein should
not also be readily detectable in urine and be incorpo-
rated, with other carefully selected mutation hotspots,
into a targeted sequencing panel for non-invasive
UBC detection. Such a test will require large-
scale validation of sensitivity, specificity and clinical
utility.
CONCLUSIONS
Mutations in the non-coding regions of GPR126,
PLEKHS1, TBC1D12, LEPROTL1, WDR74 are fre-
quent early events in UBC associated with an
APOBEC mutational signature. They are common to
both papillary-LG and CIS-HG pathways of tumour
development, and may prove to be valuable biomark-
ers for bladder cancer detection.
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